BrainQ, a Jerusalem, Israel-based developer of Artificial Intelligence (AI) powered technologies to treat neurodisorders in innovative ways, completed a new financing round.
This brings total funding to date to $8.8M.
Backers included Qure Ventures, OurCrowd.com, Norma Investments, IT-Farm, and other strategic angel investors such as Founder and CEO of Valtech Cardio Amir Gross, acquired by Edwards in a $990M deal in November 2016.
The company intends to use the funds to further develop its non-invasive, BCI-based simulation device towards commercialization activities in various markets, support clinical trials and grow the unique BCI-based EEG database.
Co-founded by Yotam Drechsler (CEO), Dr. Yaron Segal (CTO), and Prof. Emerita Esther Shohami (CSO) in 2011, BrainQ is developing technology that utilizes its proprietary AI algorithms to identify high resolution spectral patterns in patient’s brain waves. These patterns are interpreted and then translated into a tailored electromagnetic treatment protocol aimed to treat disabilities following neurodisorders such as stroke and spinal cord injury.
The company’s AI technology largely stems from developing and owning one of the largest known Brain Computer Interface (“BCI”)-based EEG databases for motor tasks.